RenovoRx (RNXT)
Develops targeted intra-arterial chemotherapy and commercializes the RenovoCath delivery device.
Something off on this page? Send us feedback.
Develops RenovoGem, an investigational drug-device candidate that delivers gemcitabine through RenovoCath, while commercializing RenovoCath as a stand-alone device. Its business combines clinical development with early cancer-center adoption.
Built around the trans-arterial micro-perfusion (TAMP) platform, the business has two connected tracks: RenovoGem, an investigational drug-device candidate that pairs intra-arterial gemcitabine with RenovoCath, and RenovoCath, an FDA-cleared delivery device sold on its own. RenovoCath entered its first full year of commercial activity in 2025, with expanding use at commercial cancer centers.
Execution centers on physician education, clinical direction, and cancer-center use of TAMP technology. Commercial growth depends on adoption and procedural utilization of RenovoCath, while the candidate path depends on clinical testing and regulatory milestones. The cleared device and investigational candidate remain distinct regulatory tracks.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.5M · Total debt $259.0K · Total assets $11.5M · Shareholders' equity $9.0M
- Revenue
- $909.0K
- Operating income
- −$3.2M
- Net income
- −$2.9M
No dividends on record.
| Institutions | 20.38% | 9.20M shares | |
|---|---|---|---|
| 29 holders · as of Jun 30, 2026 | |||
| Insiders | 14.15% | 6.39M shares | |
| 7 holders · as of Sep 15, 2026 | |||
| Other | 65.47% | 29.54M shares | |
| remainder | |||
45.13M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Orin HirschmanInsider | 9.82% | 4.43M | filed Apr 27, 2026 |
Aigh Capital Management LLCInstitution | 9.76% | 4.41M | as of Jun 30, 2026 |
Bleichroeder LPInstitution | 3.69% | 1.67M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.20% | 1.44M | as of Jun 30, 2026 |
Ramtin AgahInsiderdirector, officer: Chief Medical Officer | 1.77% | 798,460 | filed Jan 22, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 19, 2026 | Mark Voll | officer: Chief Financial Officer | +25,000 | $0.7876 |
| Mar 20, 2026 | Mark Voll | officer: Chief Financial Officer | +145,800 | $1.93 |
| Mar 20, 2026 | Shaun Bagai | director, officer: Chief Executive Officer | +36,450 | $1.93 |
| Mar 20, 2026 | Laurence Marton | director | +14,580 | $1.93 |
| Jan 21, 2026 | Ramtin Agah | director, officer: Chief Medical Officer | +10,000 | $0.9975 |
- Novocure
FDA-approved TTFields with chemotherapy for locally advanced pancreatic cancer
- Merit Medical Systems
Oncology microcatheters and embolotherapy for intra-arterial procedures
- Delcath Systems
Locoregional high-dose chemotherapy delivery for liver cancers
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| RenovoRx | $1.63 | −4.12% | $76.6M | — | — | 38.8 | +115.4% |
| Novocure | $16.09 | −3.48% | $1.94B | — | — | 2.8 | +15.6% |
| Merit Medical Systems | $87.78 | +0.60% | $5.21B | 36.1 | 20.1 | 3.3 | +9.5% |
| Delcath Systems | $15.92 | −2.93% | $566.2M | 1,261.5 | — | 5.9 | +20.6% |
| Median | 648.8 | 20.1 | 3.3 | +15.6% |